RNA Interference Targeting Angioprotein-Like Protein 3 Shows Substantial Reductions in Plasma Triglycerides, LDL-C
Gerald F. Watts, MD, presented data on behalf of the AROANG1001 study investigators on Monday at the American Heart Association Scientific Sessions 2019 in Philadelphia. The phase 1 clinical trial aimed to assess safety and efficacy of RNA inhibition of ANGPTL3, a key regulator of lipid and lipoprotein metabolism.